Transforming growth factor β in diabetic nephropathy

Diabetes/Metabolism Reviews

Volumn 12, Issue 4, 1996, Pages 309-339

  Border, Wayne A ^a   Yamamoto, Tatsuo ^b   Noble, Nancy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; DECORIN; MATRIX PROTEIN; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTAGONIST; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; FIBROGENESIS; GENE THERAPY; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

ANIMALS; DIABETIC NEPHROPATHIES; GLOMERULONEPHRITIS; HUMANS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030512150     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199612)12:4<309::AID-DMR171>3.0.CO;2-A     Document Type: Review

References (128)

1. Striker GE, Peten EP, Carome MA, Pesce CM, Schmidt K, Yang C, Elliott SJ, and Striker LJ: The kidney disease of diabetes mellitus (KDDM): A cell and molecular biology approach. Diabetes Metab Rev 9: 37-56, 1993.
2. Breyer JA: Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 19: 533-547, 1992.
3. Mauer SM: Structural-functional correlations of diabetic nephropathy. Kidney Int 45: 612-622, 1994.
4. Steffes MW, Bilous RW, Sutherland DER, and Mauer SM: Cell and matrix components of the glomerular mesangium in type I diabetes. Diabetes 41: 679-684, 1992.
5. Lane PH, Steffes MW, Fioretto P, and Mauer SM: Renal interstitial expansion in insulin-dependent diabetes rnellitus. Kidney Int 43: 661-667, 1993.
6. Border WA, and Noble NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331: 1286-4292, 1994.
7. Border WA, and Noble NA: TGF-β. Scientific Am. Science Med 2: 68-77, 1995.
8. Roberts AB, and Sporn MB: Peptide growth factors and their receptors. In The Handbook of Experimental Pharmacology, Sporn MB, and Roberts AB, Eds. Springer-Verlag, Heidelberg, 1989, pp. 419-472.
9. Sporn MB, and Roberts AB: Autocrine secretion-10 years later. Ann Intern Med 117: 408-414, 1992.
10. Nathan C, and Sporn M: Cytokines in context. J Cell Biol 113: 981-986, 1991.
11. Miyazono K, Ichijo H, and Heldin C-H: Transforming growth factor-β (TGF-β): Latent forms, binding proteins and receptors. Growth Factors 8: 11-22, 1993.
12. Ebner R, Chen R-H, Lawler S, Ziocheck T, and Derynck R: Determination of type I receptor specificity by the type II receptors for TGF-β or activin. Science 262: 900-902, 1993.
13. Lopez-Casillas F, Payne HM, Andres JL, and Massague J: Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites. J Cell Biol 124: 557-568, 1994.
14. Wrana JL, Attisano L, Wieser R, Ventura F, and Massague J: Mechanism of activation of the TGF-β receptor. Nature 370: 341-347, 1994.
15. Ruoslahti E, and Yamaguchi Y: Proteoglycans as modulators of growth factor activities. Cell 64: 867-869, 1991.
16. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, and Ross R: TGF-β induces biomodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63: 515-524, 1990.
17. Roberts AB, Joyce M, Bolander ME, and Sporn MB. Transforming growth factor-beta (TGF-β): a multifunctional effector of both soft and hard tissue regeneration. In Growth Factors in Health and Disease, Westermark B, Betsholtz C, and Hökfelt B, Eds. Elsevier, Amsterdam, 1990, pp. 89-101.
18. Wahl SM: Transforming growth factor ̈: the good, the bad, and the ugly. J Exp Med 180: 1587-1590, 1994.
19. Border WA, Okuda S, and Nakamura T: Extra-cellular matrix and glomerular disease. Semin Nephrol 9: 307-317, 1989.
20. Ruoslahti E. Integrins. J Clin Invest 87: 1-5, 1991.
21. Davidson JM: Wound repair. In Inflammation: Basic Principles and Clinical Correlates (2nd edn), Gallin JI, Goldstein IM, and Snyderman R, Eds. Raven Press, New York, 1992, pp. 809-819.
22. Border WA, and Ruoslahti E: Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 90: 1-7, 1992.
23. Fioretto P, Steffes MW, and Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 43: 1358-1364, 1994.
24. MacKay K, Striker LJ, Stauffer JW, Dois T, Agodoa LY, and Striker GE: Transforming growth factor-β. J Clin Invest 83: 1160-1167, 1989.
25. Fioretto P, Steffes MW, Brown DM, and Mauer SM: An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 20: 549-558, 1992.
26. Kaname S, Uchida S, Ogata E, and Kurokawa K: Autocrine secretion of transforming growth factor-β in cultured rat mesangial cells. Kidney Int 42: 1319-1327, 1992.
27. MacKay K, Kondaiah P, Danielpour D, Austin HA in, and Brown PD: Expression of transforming growth factor-β1 and β2 in rat glomeruli. Kidney Int 38: 1095-1100, 1990.
28. Choi ME, Kim E-G, Huang Q, and Ballermann BJ: Rat mesangial cell hypertrophy in response to transforming growth factor-β1. Kidney Int 44: 948-958, 1993.
29. Owens GK, Seisterfer AAT, Yang W-W, and Komoriya A: Transforming growth factor-β-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 107: 771-780, 1988.
30. Silver BJ, Jaffer FE, and Abboud HE: Platelet-derived growth factor synthesis in mesangial cells: induction by multiple peptide mitogens. Proc Natl Acad Sci USA 86: 1056-1060, 1989.
31. Rocco MV, Chen Y, Goldfarb S, and Ziyadeh FN: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 41: 107-114, 1992.
32. Gibbons GH, Pratt RE, and Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-β1 expression determines growth response to angiotensin II. J Clin Invest 90: 456-651, 1992.
33. Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, and Stahl RAK: TGF-β stimulates rat mesangial cell proliferation in culture: role of PDGF β-receptor expression. Am J Physiol 264 (Renal Fluid Electrolyte Physiol 33): F199-F205, 1993.
34. Jarnagin WR, Rockey DC, Koteliansky VE, Wang S-S, and Bissell DM: Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127: 2037-2048, 1994.
35. Chiquet M: Tenascin: An extracellular matrix protein involved in morphogenesis of epithelial organs. Kidney Int 41: 629-631, 1992.
36. Border WA, Okuda S, Languino LR, and Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 37: 689-695, 1990.
37. Nakamura T, Miller D, Ruoslahti E, and Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1. Kidney Int 41: 1213-1221, 1992.
38. Ziyadeh FN, and Goldfarb S: The renal tubulo-interstitium in diabetes mellitus. Kidney Int 39: 464-475, 1991.
39. Eddy AA: Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273-1287, 1994.
40. Humes HD, Nakamura T, Cieslinski DA, Miller D, Emmons RV, and Border WA: Role of proteoglycans and cytoskeleton in the effects of TGF-β1 on renal proximal tubule cells. Kidney Int 43: 575-584, 1993.
41. MacKay K, Danielpour, Miller D, Border WA, and Robbins AR: The 260-kDa transforming growth factor (TGF)-β binding protein in rat glomeruli is a complex comprised of 170- and 895-kDa TGF-β binding proteins. J Biol Chem 267: 11449-11454, 1992.
42. Tomooka S, Border WA, Marshall BC, and Noble NA: Glomerular matrix accumulation is linked to inhibition of plasmin protease system. Kidney Int 42: 1462-1469, 1992.
43. Kagami S, Border WA, Ruoslahti E, and Noble NA: Coordinated expression of β1 integrins and transforming growth factor-β-induced matrix proteins in glomerulonephritis. Lab Invest 69: 68-76, 1993.
44. Okuda S, Languino LR, Ruoslahti E, and Border WA: Elevated expression of transforming growth factor-β and proteoglycan production in experimental glomerulonephritis. J Clin Invest 86s: 453-462, 1990.
45. Miller DE, Noble NA, Yu X, and Border WA: Molecular and cellular biological techniques in the study of glomerular diseases. Semin Nephrol 12: 506-515, 1992.
46. Johnson R, Iida H, Yoshimura A, Floege J, and Bowen-Pope F: Platelet-derived growth factor: a potentially important cytokine in glomerular disease. Kidney Int 41: 590-594, 1992.
47. Border WA, Okuda S, Languino LR, Sporn MB, and Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 346: 371-374, 1990.
48. Yamamoto T, Noble NA, Miller DE, and Border WA: Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis. Kidney Int 45: 916-927, 1994.
49. Coimbra T, Wiggins R, Noh JW, Merritt S, and Phan SH: Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138: 223-234, 1991.
50. Barnes JL, and Abboud HE: Temporal expression of autocrine growth factors corresponds to morphological features of mesangial proliferation in habu snake venom-induced glomerulonephritis. Am J Pathol 143: 1366-1376, 1993.
51. Jones CL, Buch S, Post M, McCulloch L, Liu E, and Eddy AA: Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis. Kidney Int 40: 1020-1031, 1991.
52. Kaneto H, Morrissey J, Slahr S: Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44: 313-321, 1993.
53. Ishidoya S, Morrissey J, McCracken R, Reyes A, and Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 47: 1285-1294, 1995.
54. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, and Maki S: Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 68: 154-163, 1993.
55. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, and Border WA: Expression of transforming growth factor-β isoforms in human glomerular disease. Kidney Int 49: 461-469, 1996.
56. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA: Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
57. Bollineni JS, and Reddi AS: Transforming growth factor-β1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 42: 1673-1677, 1993.
58. Shankland SJ, and Scholey JW: Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int 46: 430-442, 1994.
59. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Yomino Y, and Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993.
60. Ogawa Y, Ksander GA, Pratt BM, Sawamura SJ, Ziman JM, Gerhardt CO, Avis PD, Murray MJ, and McPherson JM: Differences in the biological activities of transforming growth factor-β and platelet-derived growth factor in vivo. Growth Factors 5: 57-68, 1991.
61. Beck LS, DeGuzman L, Lee WP, Xu Y, Siegel MW, and Amento EP: One systemic administration of transforming growth factor-β1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest 92: 2841-2849, 1993.
62. Terrell TG, Working PK, Chow CP, and Green JD: Pathology of recombinant human transforming growth factor-β1 in rats and rabbits. Int Rev Exp Pathol 34: 43-67, 1993.
63. Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, and Imai E: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92: 2597-2601, 1993.
64. Floege J, Eng E, Young CA, Alpers CE, Barrett TB, Bowen-Pope DR, and Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92: 2952-2962, 1993.
65. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, and Thorgeirsson SS: Hepatic expression of mature TGF-β1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92: 2572-2576, 1995.
66. Yang C-W, Hattori M, Vlassara H, He C-J, Carome MA, Yamato E, Elliot S, Striker GE, and Striker LJ: Overexpression of transforming growth factor-β1 mRNA is associated with upregulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 5: 1610-1617, 1995.
67. Peten EP, Striker LJ, Carome MA, Elliot SJ, Yang C-W, and Striker GE: The contribution of increased collagen synthesis to human glomerulosclerosis: a quantitative analysis of α2IV collagen mRNA expression by competitive polymerase chain reaction. J Exp Med 176: 1571-1576, 1992.
68. Hostetter TH: Mechanisms of diabetic nephropathy. Am J Kidney Dis 23: 188-192, 1994.
69. Hostetter TH, Troy JL, and Brenner BM: Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19: 410-415, 1981.
70. Michels LD, Davidman M, and Keane WF: Determinants of glomerular filtration and plasma flow in experimental diabetic rats. J Lab Clin Med 98: 869-885, 1981.
71. Jensen PK, Christiansen JS, Steven K, and Parving H-H: Renal function in diabetic rats. Acta Endocrinol 242 (Suppl. 25:) 1981.
72. Gartner K: Glomerular hyperfiltration during the onset of diabetes mellitus in two strains of diabetic mice. Diabetologia 15: 59-63, 1978.
73. Hostetter TH, Tennke GH, and Brenner BM: The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375-380, 1982.
74. Zatz R and Brenner BM: Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med 80: 443-453, 1986.
75. Hostetter TH, Olson JL, Rennke HD, Venkatachalam MA, and Brenner BM: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241: F85-F93, 1981.
76. Steffes MW, Brown DM, and Mauer SM: Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 27: 35-41, 1978.
77. Zatz R, Meyer TW, Rennke HG, and Brenner GM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82: 5963-5967, 1985.
78. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke GH, and Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.
79. Rudbert S, Persson B, and Dahlquist G: Increased glomerular filtration rate and a predictor of diabetic nephropathy: an 8-year prospective study. Kidney Int 41: 822-828, 1992.
80. Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 285: 685-688, 1982.
81. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, and Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443-1447, 1987.
82. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, and Narins RG: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J Clin Invest 90: 1932-1943, 1992.
83. Riser BL, Grondin JM, Cortes P, Patterson D, and Narins RG: Mesangial cell stretch stimulates the secretion and activation of transforming growth factor beta 1 (TGF-β1), but not TGF-β2/TGF-β3. J Am Soc Nephrol 4: 663 (Abstract), 1993.
84. Wilson C, and Byrom FB: The viscious circle in chronic Bright's disease: experimental evidence from the hypertensive rat. Q J Med 10: 65-96, 1940.
85. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, and Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 19: 464-474, 1992.
86. Miller PI, Rennke HG, and Meyer TW: Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 261: F459-F465, 1991.
87. Bjorck S, Nberg G, Mulec H, Granerus G, Herlitz H, and Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293: 471-474, 1986.
88. Zatz R, Dunn BR, Meyer TW, Andersen S, Rennke HG, and Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.
89. Anderson S, Rennke HG, and Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993-2000, 1986.
90. Anderson S, Riley SL, Rennke GH, Garcia DL, and Brenner BM: Superiority of captopril over combination triple therapy in arresting diabetic glomerulopathy in the rat. Kidney Int 35: 422, 1989 (Abstract).
91. Marre M, Leblanc H, Suarez I, Guyenne T-T, Menard J, and Passa P: Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Er Med J 294: 1448-1452, 1987.
92. Mathiesen ER, Hommel E, Giese J, and Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalburninuria. Br Med J 303: 81-387, 1991.
93. Dzau VJ, Burt DW, and Pratt RE: Molecular biology of the renin-angiotensin-system. Am J Physiol 255: H563-H573, 1988.
94. Dzau VJ, Ellison KE, Brody T, Ingelfinger J, and Pratt RE: A comparative study of the distribution of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology 120: 2334-2338, 1987.
95. Paul M, Wagner J, and Dzau VJ: Gene expression of the renin-angiotensin system in human tissues. J Clin Invst 91: 2058-2064, 1993.
96. Sawa H, Tokuchi F, Mochizuki N, Endo Y, Furuta Y, Shiunohara T, Takada A, and Kawaguchi H: Expression of the angiotensinogen gene and localization of its protein in the human heart. Circulation 86: 138-146, 1992.
97. Sadoshima J, Xu Y, Slayter HS, and Izumo S: Autocrine release of angiotensin II mediates stretch induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-984, 1987.
98. Anderson S, Jung FF, and Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 265 (Renal Fluid Electrolyte Physiol 34): F455-F486, 1993.
99. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, and Fogo A: Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 42: 46-55, 1992.
100. Ketteler M, Noble N, and Border WA: Transforming growth factor-β and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis. Annu Rev Physiol 57: 279-295, 1995.
101. Anderson PW, Do YS, and Hsueh WA: Angiotensin II causes mesangial cell hypertrophy. Hypertension 21: 29-35, 1993.
102. Wolf G, Mueller E, Stahl RAK, and Ziyadeh F: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92: 1366-1372, 1993.
103. Wolf G, Haberstroh U, and Neilson EG: Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. Am J Pathol 140: 95-107, 1992.
104. Kagami S, Border WA, Miller DE, and Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 93: 2431-2437, 1994.
105. Antonipillai I, Hoang Le T, Soceneantu L, and Horton R: Transforming growth factor-β is a renin secretagogue at picomolar concentrations. Am J Physiol 265 (Renal Fluid Electrolyte Physiol 34): F537-F541, 1993.
106. Vlassara H, Bucala R, and Striker L: Pathogenic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70: 138-151, 1994.
107. Ruh H, Yang D, Striker L, Striker G, and Vlassara H: In vivo AGE-peptide injection induces kidney enlargement and glomerular hypertrophy in rabbits: prevention by aminoguanidine. Diabetes 41: 9A, 1992.
108. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, and Striker LJ: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation endproducts is mediated via plateletderived growth factor. Proc Natl Acad Sci USA 89: 2873-2877, 1992.
109. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, and Steffes M: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91; 11704-11708, 1994.
110. Yang C-W, Vlassara H, Peten EP, He C-J, Striker GE, and Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440, 1994.
111. Cohen MP, Sharma K, Jin Y, Hud E, Wu V-Y, Tomaszewski J, and Ziyadeh FN: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. J Clin Invest 95: 2338-2345, 1995.
112. Kreisberg JI: Hyperglycemia and microangiopathy: direct regulation by glucose of microvascular cells. Lab Invest 67: 416-426, 1992.
113. Ayo SH, Radnik RA, Garoni J, Glass WF, and Kreisberg JI: High glucose causes an increase in extracellular matrix proteins in cultured mesangial cells. Am J Pathol 136: 1339-1348, 1990.
114. Ayo SH, Radnik RA, Glass WF, Garoni J, Rampt ER, Appling DR, and Kreisberg JI: Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high glucose medium. Am J Physiol 260: F185-F191, 1991.
115. Ziyadeh FN, Sharma K, Ericksen M, and Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 93: 536-542, 1994.
116. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
117. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993.
118. Zeller K, Whittaker E, Sullivan L, Raskin P, and Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324: 78-84, 1991.
119. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, and Border WA: Dietary protein restriction rapidly reduces transforming growth factor β1 expression in experimental glomerulonephritis. Proc Natl Acad Sci USA 88: 9765-9769, 1991.
120. Narita I, Border WA, Ketteler M, Ruoslaht E, and Noble NA: L-Arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA 92: 4552-4556, 1995.
121. Ziyadeh FN, Sharma K, Ericksen M, and Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J Clin Invest 93: 536-542, 1994.
122. Ruoslahti E, Yamaguchi Y, Hildebrand A, and Border WA: Extracellular matrix/growth factor interactions. Cold Springs Harbor Symp Quant Biol 57: 309-315, 1992.
123. Yamaguchi Y, and Ruoslahti E: Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 336: 244-246, 1988.
124. Yamaguchi Y, Mann DM, and Ruoslahti E: Negative regulation of transforming growth factor-β by the proteoglycan decorin. Nature 346: 281-284, 1990.
125. Hildebrand A, Romaris M, Rasmussen LM, Heinegård, Twardzik DR, Border WA, and Ruoslahti E: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem J 302: 527-534, 1994.
126. Noble NA, Harper JR, and Border WA: In vivo interactions of TGF-β and extracellular matrix. Prog Growth Factor Res 4: 369-382, 1992.
127. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, and Ruoslahti E: Natural inhibitor of transforming growth factor-β against scarring in experimental kidney disease. Nature 360: 361-364, 1992.
128. Isaka Y, Brees DK, Kaneda Y, Imai E, Border WA, and Noble NA: Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease Nature Med 2: 418-423, 1996.